Abbvie Inc.

Galapagos Nv

Abbvie S.a.r.l.

Abbvie Overseas Sarl

Marc J Scanio

William H Bunnelle

Lei Shi

Michael R Schrimpf

John R Koenig

Chih-hung Lee

Tao Li

Gregory A Gfesser

Bo Liu

Andrew Bogdan

Marlon D Cowart

Robert J Altenbach

Kevin B Sippy

Philip R Kym

David A DeGoey

Ming Clinton Yeung

Xenia Beebe Searle

Diana L Nersesian

Xueqing Wang

Ramin Faghih

Murali Gopalakrishnan

Mark A Matulenko

Kathleen Mortell

Stephen N Greszler

Min Hu

Diana L Donnelly-Roberts

Jianguo Ji

Geoff G Z Zhang

Rodger F Henry

Meena V Patel

Arturo Perez-Medrano

Sridhar Peddi

Michael E Kort

Huaqing Liu

Karine Fabienne Malagu

Derek W Nelson

Nicolas Desroy

Sachin V Patel

Shuang Chen

Tammie K Jinkerson

Irini Akritopoulou-Zanze

Ying Wang

Paul J Brackemeyer

Jason T Brewer

Brian D Wakefield

Gang Zhao

Hillary M Peltier

William A Carroll

Clara I Villamil

Anil Vasudevan

Jennifer M Frost

Jerome F Daanen

Kevin R Woller

Kristine E Frank

Jyoti R Patel

Michael M Friedman

Eric A Voight

Kathy A Sarris

Vincent S Chan

Maria A Argiriadi

Shashank Shekhar

Kerren Kalai Swinger

Eric C Breinlinger

Timothy A Grieme

Christopher Gaëtan Housseman

Augustine Osuma

Béranger Duthion

Xiangdong Xu

Bruce Clapham

Sylvain Couty

Elsa De Lemos

J Martin Herold

Steve Latshaw

Diana L Schmidt

Jennifer Van Camp

Stacy A Van Epps

Ana Aguirre

Matthew P Webster

Ellen Yulin Tsai Chien

David J Hardee

Wei Qiu

Thomas R Vargo

Andrew J Little

Xeuquing Wang

William Ramesh Esmieu

Chih-Hung Lee

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R2, R, R, R, X, X, X, X, X, nad n are as defined herein, pharmaeceutical compositions 2C X, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use. 

Inhibitors of tyrosine kinase 2 mediated signaling

The invention discloses compounds of Formula (I) wherein R, R, R, R, R, R, and Rare as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Substituted pyrrolidines and methods of use

The present invention provides for compounds of formula (I) wherein R, m, Z, G, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj&#xf6;gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Modulators of cystic fibrosis transmembrane conductance regulator protein

The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) wherein a, R, R, R, R, R, U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Indole and indoline derivatives and methods of use thereof

The invention discloses compounds of Formula (I) wherein R, R, R, R, R, R, R, and Rare as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R, R, and Rare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Na1.7 and/or Na1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use

The present invention provides for compounds of formula (I) wherein X, Y, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj&#xf6;gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Substituted tricyclics and method of use

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein A, Rand Rare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Na1.7 and/or Na1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Indazole ureas and method of use

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R, Z, Z, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Furo-3-carboxamide derivatives and methods of use

The present application relates to benzodiazepine and pyridodiazepine derivatives of formula (I) wherein R, R, R, R, X, Y, Y, and Yare as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Benzodiazepine and pyridodiazepine derivatives

The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Azaadamantane derivatives and methods of use

Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein ring G, X, R, and Rare as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

Potassium channel modulators

Growing community of inventors

Libertyville, IL, United States of America

Marc J Scanio